ECSP088294A - Formulación en aerosol para la inhalación de beta-agonistas - Google Patents

Formulación en aerosol para la inhalación de beta-agonistas

Info

Publication number
ECSP088294A
ECSP088294A EC2008008294A ECSP088294A ECSP088294A EC SP088294 A ECSP088294 A EC SP088294A EC 2008008294 A EC2008008294 A EC 2008008294A EC SP088294 A ECSP088294 A EC SP088294A EC SP088294 A ECSP088294 A EC SP088294A
Authority
EC
Ecuador
Prior art keywords
inhalation
aerosol formulation
agonists
beta
radicals
Prior art date
Application number
EC2008008294A
Other languages
English (en)
Inventor
Humke Barbara Niklaus
Michael Nowak
Kirsten Radau
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of ECSP088294A publication Critical patent/ECSP088294A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invención se refiere a una formulación en aerosol sin gas propelente que contiene uno o varios compuestos de la fórmula general 1, 1en donde los radicales R1, R2, R3 y X- pueden tener los significados mencionados en las reivindicaciones y en la descripción, y otro principio activo 2, para la inhalación..
EC2008008294A 2005-10-10 2008-03-19 Formulación en aerosol para la inhalación de beta-agonistas ECSP088294A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05109376 2005-10-10

Publications (1)

Publication Number Publication Date
ECSP088294A true ECSP088294A (es) 2008-04-28

Family

ID=35241312

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008294A ECSP088294A (es) 2005-10-10 2008-03-19 Formulación en aerosol para la inhalación de beta-agonistas

Country Status (31)

Country Link
US (3) US20070088030A1 (es)
EP (1) EP1940349B1 (es)
JP (1) JP2009511542A (es)
KR (1) KR20080059290A (es)
CN (1) CN101282712A (es)
AR (1) AR058082A1 (es)
AU (1) AU2006301330B9 (es)
BR (1) BRPI0617278A2 (es)
CA (1) CA2624786C (es)
CY (1) CY1120199T1 (es)
DK (1) DK1940349T3 (es)
EA (1) EA200800927A1 (es)
EC (1) ECSP088294A (es)
ES (1) ES2668364T3 (es)
HR (1) HRP20180713T1 (es)
HU (1) HUE039186T2 (es)
IL (1) IL190682A (es)
LT (1) LT1940349T (es)
MY (1) MY163503A (es)
NO (1) NO343363B1 (es)
NZ (1) NZ567545A (es)
PE (1) PE20070708A1 (es)
PL (1) PL1940349T3 (es)
PT (1) PT1940349T (es)
RS (1) RS57085B1 (es)
SI (1) SI1940349T1 (es)
TW (1) TWI389692B (es)
UA (1) UA99250C2 (es)
UY (1) UY29844A1 (es)
WO (1) WO2007042468A2 (es)
ZA (1) ZA200801390B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
MX2008001976A (es) * 2005-08-15 2008-03-25 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
US20110319402A1 (en) * 2008-11-21 2011-12-29 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
WO2010057928A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
WO2014056840A1 (en) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US20140235627A1 (en) * 2012-12-21 2014-08-21 Boehringer Ingelheim International Gmbh ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
ES2826562T3 (es) * 2015-05-18 2021-05-18 Glenmark Specialty Sa Solución para inhalación de tiotropio por nebulizador
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
US20210322311A1 (en) * 2020-04-16 2021-10-21 Cai Gu Huang Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol
CN114259481A (zh) * 2021-11-26 2022-04-01 南京华盖制药有限公司 一种奥达特罗复方吸入溶液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
PL177078B1 (pl) * 1992-12-09 1999-09-30 Boehringer Ingelheim Pharma Preparaty roztworów aerozolowych
WO2001083462A1 (de) * 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE10216036A1 (de) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
BRPI0510080B8 (pt) * 2004-04-22 2021-05-25 Boehringer Ingelheim Int combinação farmacêutica e seu uso
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists

Also Published As

Publication number Publication date
ES2668364T3 (es) 2018-05-17
JP2009511542A (ja) 2009-03-19
NO343363B1 (no) 2019-02-11
TW200730178A (en) 2007-08-16
SI1940349T1 (en) 2018-05-31
EA200800927A1 (ru) 2008-10-30
US20070088030A1 (en) 2007-04-19
MY163503A (en) 2017-09-15
CY1120199T1 (el) 2018-12-12
RS57085B1 (sr) 2018-06-29
IL190682A0 (en) 2008-11-03
PE20070708A1 (es) 2007-08-06
EP1940349A2 (de) 2008-07-09
ZA200801390B (en) 2009-01-28
US20100009984A1 (en) 2010-01-14
BRPI0617278A2 (pt) 2011-07-19
TWI389692B (zh) 2013-03-21
UY29844A1 (es) 2007-05-31
AU2006301330B9 (en) 2013-01-17
HRP20180713T1 (hr) 2018-06-15
NZ567545A (en) 2011-07-29
DK1940349T3 (en) 2018-05-28
CN101282712A (zh) 2008-10-08
KR20080059290A (ko) 2008-06-26
EP1940349B1 (de) 2018-02-14
AU2006301330B2 (en) 2012-11-22
US20110190284A1 (en) 2011-08-04
IL190682A (en) 2015-06-30
UA99250C2 (ru) 2012-08-10
WO2007042468A3 (de) 2007-08-02
AU2006301330A1 (en) 2007-04-19
CA2624786A1 (en) 2007-04-19
NO20080801L (no) 2008-04-29
PT1940349T (pt) 2018-04-30
LT1940349T (lt) 2018-05-10
HUE039186T2 (hu) 2018-12-28
WO2007042468A2 (de) 2007-04-19
AR058082A1 (es) 2008-01-23
CA2624786C (en) 2015-06-16
PL1940349T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
ECSP088294A (es) Formulación en aerosol para la inhalación de beta-agonistas
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
ECSP067004A (es) Formulación en aerosol para la inhalación de beta-agonistas
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
ATE433447T1 (de) Pyrimiidinverbindungen
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
ECSP088246A (es) Nuevos derivados de benzotiazolona
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CR9268A (es) Nuevo derivado de diazabiciclononeno
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY27980A1 (es) Indoles 2,7-sustituidos
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
NO20081587L (no) Aerosolformulering for inhalering
UY30555A1 (es) Formulacion aerosol para la inhalacion de beta-agonistas
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer